Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Case Report

Open Access Gateway

Reversible Valproate Induced Pisa Syndrome and Parkinsonism in a Neuro-Oncology Patient with Depression and Epilepsy

Botturi A.a,b · Silvani A.a · Pravettoni G.d,e · Paoli R.A.b · Lucchiari C.c

Author affiliations

aDepartment of Neuro-Oncology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
bDepartment of Psychiatry, Università degli Studi di Milano, Fondazione IRCCS Ca’Granda Ospedale Maggiore Policlinico, Milan, Italy
cDepartment of Philosophy, Università degli Studi di Milano, Milan, Italy
dDepartment of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy
eApplied Research Unit for Cognitive and Psychological Science, European Institute of Oncology, Milan, Italy

Corresponding Author

Andrea Botturi

Via Celoria 11

IT–20133 Milan (Italy)

andrea.botturi@istituto-besta.it

Related Articles for ""

Case Rep Neurol 2016;8:115–119

Do you have an account?

Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



Abstract

Neurological and psychiatric conditions frequently overlap in neuro-oncology. This overlapping negatively affects patients’ quality of life and decreases the ability of providers to manage specific symptoms by therapy modulation, especially when psychopharmacotherapy needs to be prescribed. We describe here a patient with recurrent brain tumor, symptomatic epilepsy and depression who developed Pisa syndrome and parkinsonism after several months of valproic acid use. An accurate recognition of symptoms and treatment side effect allowed an appropriate clinical approach so as to rapidly improve both movement disorder and depression without increasing the risk of developing seizure. This has improved the autonomy and quality of life in a patient with poor prognosis.

© 2016 The Author(s). Published by S. Karger AG, Basel


References

  1. Rooney AG, McNamara S, Mackinnon M, Fraser M, Rampling R, Carson A, Grant R: Frequency, clinical associations, and longitudinal course of major depressive disorder in adults with cerebral glioma. J Clin Oncol 2011;29: 4307–4312.
  2. Rooney AG, Brown PD, Reijneveld JC, Grant R: Depression in glioma: a primer for clinicians and researchers. J Neurol Neurosurg Psychiatry 2014;85: 230–235.
  3. Opbroek A, Delgado PL, Laukes C, McGahuey C, Katsanis J, Moreno FA, Manber R: Emotional blunting associated with SSRI-induced sexual dysfunction. Do SSRIs inhibit emotional responses? Int J Neuropsychopharmacol 2002;5: 147–151.
  4. Dell’Agnello G, Ceravolo R, Nuti A, Bellini G, Piccinni A, D’Avino C, Dell’Osso L, Bonuccelli U: SSRIs do not worsen Parkinson’s disease: evidence from an open-label, prospective study. Clin Neuropharmacol 2001;24: 221–227.
  5. Vecht CJ, Kerkhof M, Duran-Pena A: Seizure prognosis in brain tumors: new insights and evidence-based management. Oncologist 2014;19: 751–759.
  6. Alper K, Schwartz KA, Kolts RL, Khan A: Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol Psychiatry 2007;62: 345–354.
  7. Maguire MJ, Weston J, Singh J, Marson AG: Antidepressants for people with epilepsy and depression. Cochrane Database Syst Rev 2014;12:CD010682.
  8. Lambert PA, Carraz G, Borselli S, Carbel S: Neuropsychotropic action of a new anti-epileptic agent: depamide. Ann Med Psychol (Paris) 1966;124: 707–710.
    External Resources
  9. Nanau RM, Neuman MG: Adverse drug reactions induced by valproic acid. Clin Biochem 2013;46: 1323–1338.
  10. Madhusoodanan S, Velama U, Parmar J, Goia D, Brenner R: A current review of cytochrome P450 interactions of psychotropic drugs. Ann Clin Psychiatry 2014;26: 120–138.
    External Resources
  11. Ekbom K, Lindholm H, Ljungberg L: New dystonic syndrome associated with butyrophenone therapy. Z Neurol 1972;202: 94–103.
  12. Matsuo F, Bergen D, Faught E, Messenheimer JA, Dren AT, Rudd GD, Lineberry CG: Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. U.S. Lamotrigine Protocol 0.5 Clinical Trial Group. Neurology 1993;43: 2284–2291.
  13. Reid JG, Gitlin MJ, Altshuler LL: Lamotrigine in psychiatric disorders. J Clin Psychiatry 2013;74: 675–684.
  14. Bruno A, Micò U, Pandolfo G, Mallamace D, Abenavoli E, Di Nardo F, D’Arrigo C, Spina E, Zoccali RA, Muscatello MR: Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J Psychopharmacol 2012;26: 1456–1462.
  15. Chang CM, Sato S, Han C: Evidence for the benefits of nonantipsychotic pharmacological augmentation in the treatment of depression. CNS Drugs 2013; 27(suppl 1):S21–S27.

Article / Publication Details

Received: January 27, 2016
Accepted: May 09, 2016
Published online: June 06, 2016
Issue release date: May – August

Number of Print Pages: 5
Number of Figures: 1
Number of Tables: 1


eISSN: 1662-680X (Online)

For additional information: https://www.karger.com/CRN


Open Access License / Drug Dosage / Disclaimer

This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.